Indeed, αGAL-9 antibody treatment of ACM-exposed B-ALL cells suppressed or ablated the protein levels of key cell cycle checkpoint regulators (Cyclin A/Cyclin D3/CDK2/CDK4) except for the cell cycle promoting transcription factor E2F1. This evidence concerns the gene CDK2 and precursor B-cell acute lymphoblastic leukemia.